The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021

Basit Öğe Kaydı
dc.contributor.authorAnders, Hans-Joachim
dc.contributor.authorLoutan, Jerome
dc.contributor.authorBruchfeld, Annette
dc.contributor.authorFernandez-Juarez, Gema M.
dc.contributor.authorFloege, Juergen
dc.contributor.authorGoumenos, Dimitrios
dc.contributor.authorTurkmen, Kultigin
dc.date.accessioned2024-02-23T14:21:02Z
dc.date.available2024-02-23T14:21:02Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractIn 2019 and 2021, the European League for Rheumatism (EULAR) jointly with the European Renal Association (ERA) and the Kidney Disease: Improving Global Outcomes (KDIGO), respectively, released updated guidelines on the management of lupus nephritis (LN). The Immunology Working Group of the ERA reviewed and compared both updates. Recommendations were either consistent or differences were of negligible clinical relevance for: indication for kidney biopsy, kidney biopsy interpretation, treatment targets, hydroxychloroquine dosing, first-line initial immunosuppressive therapy for active class III, IV (+/- V) LN, pregnancy in LN, LN in paediatric patients and LN patients with kidney failure. Relevant differences in the recommended management relate to the recognition of lupus podocytopathies, uncertainties in steroid dosing, drug preferences in specific populations and maintenance therapy, treatment of pure class V LN, therapy of recurrent LN, evolving alternative drug options and diagnostic work-up of thrombotic microangiopathy. Altogether, both documents provide an excellent guidance to the growing complexity of LN management. This article endeavours to prevent confusion by identifying differences and clarifying discrepancies.en_US
dc.description.sponsorshipDeutsche Forschungsgemeinschaft [AN372/29-1, 30-1]en_US
dc.description.sponsorshipThe Immunonephrology Working Group receives financial and logistic support from ERA. H.-J.A. was supported by the Deutsche Forschungsgemeinschaft (AN372/29-1 and 30-1).en_US
dc.identifier.doi10.1093/ndt/gfab351
dc.identifier.endpage561en_US
dc.identifier.issn0931-0509
dc.identifier.issn1460-2385
dc.identifier.issue3en_US
dc.identifier.pmid34888694en_US
dc.identifier.scopus2-s2.0-85129606914en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage551en_US
dc.identifier.urihttps://doi.org/10.1093/ndt/gfab351
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13418
dc.identifier.volume38en_US
dc.identifier.wosWOS:000767415000001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofNephrology Dialysis Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAutoimmunityen_US
dc.subjectGlomerulonephritisen_US
dc.subjectInflammationen_US
dc.subjectLupusen_US
dc.subjectStandardsen_US
dc.titleThe management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu